Changes in the pharmacokinetics of lurasidone in a pregnant woman with schizophrenia
Decreased serum lurasidone levels during pregnancy may increase the risk of symptom worsening in patients with schizophrenia. Hence, clinicians should be knowledgeable about the risk of decreased drug levels and the need for therapeutic monitoring and dosage adjustments during pregnancy to maintain treatment efficacy and maternal and fetal health.
Authors
- Mihoko Kawai (ORCID: https://orcid.org/0000-0002-0965-5092)
- Tadashi Ogawa
- Ryosuke Aratake
Institutions
- Aichi Medical University (JP)
Publication Details
- Journal
- Psychiatry and Clinical Neurosciences Reports
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/pcn5.70043
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00